Amylyx Pharmaceuticals' Co-CEO Sells $1.9M in Shares Amid Company's Strong Performance

Amylyx Pharmaceuticals Co-Chief Executive Joshua B Cohen sold 138,167 shares for $1.9 million on Jan. 15 and 16, 2026, reducing his direct holdings by 3.93%. The sale was to cover option costs and tax obligations. Amylyx Pharmaceuticals had a strong year in 2025, soaring approximately 223%, with its flagship therapy, AMX0035, showing promise in treating ALS. The company is also advancing a product candidate, avexitide, to treat hypoglycemia and hyperinsulinism.